Novartis Alcon Separation And Distribution Agreement

  • Non classé

Forward-looking statements are neither historical facts nor assurances of future achievements. Instead, they are based solely on Alcon`s current beliefs, expectations and assumptions about the future of its business, future plans and strategies and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. These forward-looking statements are subject to various risks and uncertainties facing Alcon, including: the commercial success of its products and its ability to maintain and strengthen its position in its markets; The success of its research and development efforts; Uncertainties about the success of Alcon`s separation and demerger from Novartis, including the expected separation and transformation costs and potential savings achieved by Alcon; Price pressure by changing the methods of compensation and reimbursement of third parties; global economic, financial, legal, fiscal, political and social changes; Ongoing consolidation of the sector; its ability to maintain relationships in the health sector Changes to customers` inventory or purchasing patterns their dependence on limited or exclusive sources of supply; its dependence on the outsourcing of important business functions; its ability to protect its intellectual property the impact on unauthorized importation of their products from countries with lower prices in countries with higher prices; Successful completion and integration of strategic acquisitions; The consequences of litigation, including product liability actions; its ability to comply with all laws to which it may be subject; The effects of product recalls or voluntary withdrawals from the market, including CyPass; Data protection violations Implementing the company`s resource planning system its ability to attract and retain qualified staff; The adequacy of their insurance coverage The veracity of its estimates and assumptions, including pension commitments and the book value of intangible assets; the possibility of obtaining administrative authorization and authorisation of its products, as well as compliance with any obligations after approval; legislation and regulation reform; Alcon Pharmaceuticals Ltd.

Fermer le menu